Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Perspective Therapeutics ...

    AMEX: CATX · Real-Time Price · USD
    3.17
    -0.05 (-1.55%)
    At close: Jun 13, 2025, 3:59 PM
    3.16
    -0.32%
    After-hours: Jun 13, 2025, 05:31 PM EDT

    Perspective Therapeutics Statistics

    Share Statistics

    Perspective Therapeutics has 74.23M shares outstanding. The number of shares has increased by 9.82% in one year.

    Shares Outstanding

    n/a
    		 74.23M

    Shares Change (YoY)

    n/a
    		 9.82%

    Shares Change (QoQ)

    n/a
    		 9.56%

    Owned by Institutions (%)

    n/a
    		 n/a

    Shares Floating

    n/a
    		 54.14M

    Failed to Deliver (FTD) Shares

    n/a
    		 1,847

    FTD / Avg. Volume

    n/a
    		 0.19%

    Short Selling Information

    The latest short interest is 5.28M, so 7.11% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 5.28M

    Short % of Shares Out

    n/a
    		 7.11%

    Short % of Float

    n/a
    		 10.07%

    Short Ratio (days to cover)

    n/a
    		 5.97

    Valuation Ratios

    The PE ratio is -2.59 and the forward PE ratio is -2.5. Perspective Therapeutics's PEG ratio is 0.09.

    PE Ratio

    n/a
    		 -2.59

    Forward PE

    n/a
    		 -2.5

    PS Ratio

    n/a
    		 0

    Forward PS

    n/a
    		 0.8

    PB Ratio

    n/a
    		 0.71

    P/FCF Ratio

    n/a
    		 -2.83

    PEG Ratio

    n/a
    		 0.09
    Financial Ratio History

    Enterprise Valuation

    Currently the Enterprise Value (EV) is not available for Perspective Therapeutics.

    EV / Sales

    n/a
    		 n/a

    EV / EBITDA

    n/a
    		 n/a

    EV / EBIT

    n/a
    		 n/a

    EV / FCF

    n/a
    		 n/a

    Financial Position

    The company has a current ratio of 12.68, with a Debt / Equity ratio of 0.01.

    Current Ratio

    n/a
    		 12.68

    Quick Ratio

    n/a
    		 12.68

    Debt / Equity

    n/a
    		 0.01

    Debt / EBITDA

    n/a
    		 0.23

    Debt / FCF

    n/a
    		 -0.03

    Interest Coverage

    n/a
    		 -217.9

    Financial Efficiency

    Return on Equity is n/a and Return on Invested Capital is n/a.

    Return on Equity

    n/a
    		 n/a

    Return on Assets

    n/a
    		 n/a

    Return on Invested Capital

    n/a
    		 n/a

    Revenue Per Employee

    n/a
    		 n/a

    Profits Per Employee

    n/a
    		 $-574,485.51

    Employee Count

    n/a
    		 138

    Asset Turnover

    n/a
    		 0

    Inventory Turnover

    n/a
    		 n/a

    Taxes

    Income Tax

    n/a
    		 -2.1M

    Effective Tax Rate

    n/a
    		 2.58%

    Stock Price Statistics

    The stock price has increased by -70.37% in the last 52 weeks. The beta is 1.12, so Perspective Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 1.12

    52-Week Price Change

    n/a
    		 -70.37%

    50-Day Moving Average

    n/a
    		 2.46

    200-Day Moving Average

    n/a
    		 5.85

    Relative Strength Index (RSI)

    n/a
    		 59.22

    Average Volume (20 Days)

    n/a
    		 989,971

    Income Statement

    Revenue

    n/a
    		 n/a

    Gross Profit

    n/a
    		 n/a

    Operating Income

    n/a
    		 10.46M

    Net Income

    n/a
    		 -79.28M

    EBITDA

    n/a
    		 10.46M

    EBIT

    n/a
    		 -81.42M

    Earnings Per Share (EPS)

    n/a
    		 -1.23
    Full Income Statement

    Balance Sheet

    The company has 61.58M in cash and 2.38M in debt, giving a net cash position of 59.2M.

    Cash & Cash Equivalents

    n/a
    		 61.58M

    Total Debt

    n/a
    		 2.38M

    Net Cash

    n/a
    		 59.2M

    Retained Earnings

    n/a
    		 -231.72M

    Total Assets

    n/a
    		 341.1M

    Working Capital

    n/a
    		 212.93M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -18.29M and capital expenditures -54.41M, giving a free cash flow of -72.71M.

    Operating Cash Flow

    n/a
    		 -18.29M

    Capital Expenditures

    n/a
    		 -54.41M

    Free Cash Flow

    n/a
    		 -72.71M

    FCF Per Share

    n/a
    		 -1.13
    Full Cash Flow Statement

    Margins

    Gross Margin

    n/a
    		 n/a

    Operating Margin

    n/a
    		 n/a

    Pretax Margin

    n/a
    		 n/a

    Profit Margin

    n/a
    		 n/a

    EBITDA Margin

    n/a
    		 n/a

    EBIT Margin

    n/a
    		 n/a

    FCF Margin

    n/a
    		 n/a

    Dividends & Yields

    CATX does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 n/a

    FCF Yield

    n/a
    		 n/a
    Dividend Details

    Analyst Forecast

    The average price target for CATX is $13, which is 310.1% higher than the current price. The consensus rating is "Buy".

    Price Target

    n/a
    		 $13

    Price Target Difference

    n/a
    		 310.1%

    Analyst Consensus

    n/a
    		 Buy

    Analyst Count

    n/a
    		 9
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 n/a

    Graham Upside

    n/a
    		 n/a

    Stock Splits

    The last stock split was on Jun 17, 2024. It was a backward split with a ratio of 1:10.

    Last Split Date

    n/a
    		 Jun 17, 2024

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:10

    Scores

    Altman Z-Score

    n/a
    		 1.28

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist